



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMADOC-1700519818-2035699

## European Medicines Agency decision

EMA/PE/0000229486

of 14 April 2025

on the acceptance of a modification of an agreed paediatric investigation plan for alanine, arginine, aspartic acid, calcium chloride dihydrate, deferoxamine mesilate, glycine, histidine, L-tryptophan, magnesium chloride hexahydrate, N-acetylhistidine monohydrate, N-hydroxy-3,4-dimethoxy-N-methylbenzamide, oxogluric acid, potassium chloride, sodium chloride in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

### **Disclaimer**

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**



# European Medicines Agency decision

EMA/PE/0000229486

of 14 April 2025

on the acceptance of a modification of an agreed paediatric investigation plan for alanine, arginine, aspartic acid, calcium chloride dihydrate, deferoxamine mesilate, glycine, histidine, L-tryptophan, magnesium chloride hexahydrate, N-acetylhystidine monohydrate, N-hydroxy-3,4-dimethoxy-N-methylbenzamide, oxogluric acid, potassium chloride, sodium chloride in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the European Medicines Agency's decision P/0213/2023 issued on 14 June 2023, the decision P/0190/2021 issued on 10 May 2021 and the decision P/0484/2021 issued on 3 December 2021,

Having regard to the application submitted by Dr. Franz Koehler Chemie GmbH on 23 November 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 28 February 2025, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan including changes to the deferral.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1, as amended.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

**Article 1**

Changes to the agreed paediatric investigation plan for alanine, arginine, aspartic acid, calcium chloride dihydrate, deferoxamine mesilate, glycine, histidine, L-tryptophan, magnesium chloride hexahydrate, N-acetylhistidine monohydrate, N-hydroxy-3,4-dimethoxy-N-methyl-benzamide, oxogluric acid, potassium chloride, sodium chloride, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

**Article 2**

This decision is addressed to Dr. Franz Koehler Chemie GmbH, Werner-Von-Siemens-Strasse 14-28, 64625 - Bensheim, Germany.



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMADOC-1700519818-1802654 Corr<sup>1</sup>

Amsterdam, 28 February 2025

## Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA/PE/0000229486

### Scope of the application

#### Active substance(s):

Alanine, arginine, aspartic acid, calcium chloride dihydrate, deferoxamine mesilate, glycine, histidine, L-tryptophan, magnesium chloride hexahydrate, N-acetylhistidine monohydrate, N-hydroxy-3,4-dimethoxy-N-methyl-benzamide, oxogluric acid, potassium chloride, sodium chloride

#### Invented name and authorisation status:

See Annex II

#### Condition(s):

Heart transplantation

#### Pharmaceutical form(s):

Solution for organ preservation

#### Route(s) of administration:

Not applicable

#### Name/corporate name of the PIP applicant:

Dr. Franz Koehler Chemie GmbH

### Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Dr. Franz Koehler Chemie GmbH submitted to the European Medicines Agency on 23 November 2024 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0213/2023 issued on 14 June 2023, the decision P/0190/2021 issued on 10 May 2021 and the decision P/0484/2021 issued on 3 December 2021.

---

<sup>1</sup> 10 April 2025



The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 2 January 2025.

## **Scope of the modification**

Some measures and timelines of the Paediatric Investigation Plan have been modified.

## **Opinion**

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
  - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

## **Annex I**

**The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)**

# 1. Waiver

Not applicable

## 2. Paediatric investigation plan

### 2.1. Condition:

Heart transplantation

#### 2.1.1. Indication(s) targeted by the PIP

Preservation of hearts prior to heart transplantation

#### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

#### 2.1.3. Pharmaceutical form(s)

Solution for organ preservation

#### 2.1.4. Measures

Area	Description
Quality-related studies	Not applicable
Non-clinical studies	<b>Study 1 (FKC-001_02_rat_tox_iv)</b> Single dose intravenous toxicity study of 3,4-dimethoxy-N-methylbenzohydroxamic acid in rats <b>Study 2 (FKC-003_01_dev_reprotox Rat)</b> Reproductive toxicity study of 3,4-dimethoxy-N-methylbenzohydroxamic acid in rats
Clinical studies	<b>Study 3 (CL-N-HTX-Paed-II/10/20)</b> Randomised single-blind study to compare the safety of the investigational preservation solution to that of its precursor product in children from birth to less than 18 years of age undergoing heart transplantation
Extrapolation, modelling and simulation studies	Not applicable
Other studies	Not applicable
Other measures	Not applicable

### 3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By March 2027
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

## **Annex II**

### **Information about the authorised medicinal product**

***Information provided by the applicant:***

**The product is not authorised anywhere in the European Community.**